文献速递银屑病与炎症性皮肤病

Bimekizumab治疗中重度斑块状银屑病:BE ABLE 2随机双盲安慰剂对照2b期扩展研究60周结果

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
PubMed 文献 · J Am Acad Dermatol · 2020-05-29

BE ABLE 2为2b期扩展研究,纳入BE ABLE 1第12周达到PASI 90的患者,继续接受bimekizumab 64、160或320 mg治疗48周(共60周),主要目标为安全性。全部剂量组(N=217)第60周PASI 90应答率维持80%至100%,PASI 100为69%至83%,IGA 0/1为78%至100%(非应答者填补);严重治疗中出现不良事件发生率为15/217(6.9%),未报告炎症性肠病、主要不良心血管事件或自杀意念/行为。

要点

  • 第12周PASI 90应答者继续bimekizumab至60周,PASI 90维持80%至100%。
  • PASI 100达69%至83%,IGA 0/1达78%至100%(非应答者填补)。
  • 严重治疗中出现不良事件15/217(6.9%),未报告IBD、MACE或自杀相关事件。

核心结论

  • Bimekizumab应答率维持至第60周,相当比例患者达到完全皮损清除,总体耐受良好。

研究设计与样本

  • BE ABLE 2为随机双盲安慰剂对照2b期扩展研究,纳入BE ABLE 1第12周PASI 90患者,继续bimekizumab 64、160或320 mg治疗48周(共60周),主要目标为安全性。

主要发现

  • 全部剂量组(N=217)第60周PASI 90应答率80%至100%,PASI 100为69%至83%,IGA 0/1为78%至100%(非应答者填补)。
  • 严重治疗中出现不良事件发生率为15/217(6.9%)。
  • 未报告炎症性肠病、主要不良心血管事件或自杀意念/行为。

关键数值与推荐

  • 第60周PASI 90:80%至100%;PASI 100:69%至83%;IGA 0/1:78%至100%(非应答者填补)。
  • 严重治疗中出现不良事件:15/217(6.9%)。

临床怎么用

  • 对第12周达到PASI 90的中重度斑块状银屑病患者,bimekizumab 64、160或320 mg治疗至60周可维持高应答且总体耐受良好。

局限性

  • bimekizumab 64 mg组样本量小(n=15)。
  • 报告的60周数据主要来自第12周PASI 90应答者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual neutralization of both interleukin 17A and 17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin 17A alone. OBJECTIVE: To provide longer-term efficacy and safety data for bimekizumab from a phase 2b extension study in patients with moderate to severe psoriasis (BE ABLE 2). METHODS: After the 12-week initial study (BE ABLE 1), patients who had a 90% improvement in Psoriasis Area and Severity Index (PASI 90) at week 12 received bimekizumab 64, 160, or 320 mg for an additional 48 weeks (60 weeks in total). The primary objective was safety. RESULTS: Across all dose groups (N = 217), initial PASI 90 responders generally maintained high levels of efficacy through week 60: PASI 90, 80% to 100%; 100% improvement in PASI, 69% to 83%; Investigator's Global Assessment score 0 or 1, 78% to 100% (all nonresponder imputation). Incidence of serious treatment-emergent adverse events was 15/217 (6.9%). No cases of inflammatory bowel disease, major adverse cardiovascular events, or suicidal ideation or behavior were reported. LIMITATIONS: Low numbers in the bimekizumab 64 mg group (n = 15). The majority of 60-week data reported here are primarily for the week 12 PASI 90 responders only. CONCLUSION: Bimekizumab response rates were maintained through week 60. A substantial proportion of patients achieved complete skin clearance. Bimekizumab was generally well tolerated.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020. PMID: 32473974. doi:10.1016/j.jaad.2020.05.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。